A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease

Alireza Faridar; Abdulmunaim M Eid; Aaron D Thome; Weihua Zhao; David R Beers; Maria B Pascual; Mohammad O Nakawah; Gustavo C Roman; Charles S Davis; Michael Grundman; Joseph C Masdeu; Stanley H Appel

doi:10.1186/s40035-023-00387-5

A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease

Alireza Faridar, Abdulmunaim M Eid, Aaron D Thome, Weihua Zhao, David R Beers, Maria B Pascual, Mohammad O Nakawah, Gustavo C Roman, Charles S Davis, Michael Grundman, Joseph C Masdeu, Stanley H Appel

Research output: Contribution to journal › Letter › peer-review

24 Scopus citations

Abstract

Trial registration : ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT05821153.

Original language	English (US)
Article number	54
Pages (from-to)	54
Journal	Translational Neurodegeneration
Volume	12
Issue number	1
DOIs	https://doi.org/10.1186/s40035-023-00387-5
State	Published - Nov 16 2023

Keywords

Humans
Alzheimer Disease/drug therapy
Pilot Projects
Treatment Outcome
Immunotherapy

ASJC Scopus subject areas

Clinical Neurology
Cognitive Neuroscience
Cellular and Molecular Neuroscience

Access to Document

10.1186/s40035-023-00387-5

Cite this

Faridar, A., Eid, A. M., Thome, A. D., Zhao, W., Beers, D. R., Pascual, M. B., Nakawah, M. O., Roman, G. C., Davis, C. S., Grundman, M., Masdeu, J. C., & Appel, S. H. (2023). A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease. Translational Neurodegeneration, 12(1), 54. Article 54. https://doi.org/10.1186/s40035-023-00387-5

@article{67e299eb31934e91969fffd349523420,

title = "A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer{\textquoteright}s disease",

abstract = "Trial registration : ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT05821153.",

keywords = "Humans, Alzheimer Disease/drug therapy, Pilot Projects, Treatment Outcome, Immunotherapy",

author = "Alireza Faridar and Eid, \{Abdulmunaim M\} and Thome, \{Aaron D\} and Weihua Zhao and Beers, \{David R\} and Pascual, \{Maria B\} and Nakawah, \{Mohammad O\} and Roman, \{Gustavo C\} and Davis, \{Charles S\} and Michael Grundman and Masdeu, \{Joseph C\} and Appel, \{Stanley H\}",

note = "Funding Information: This research was supported by the Alzheimer{\textquoteright}s Association Part-The-Cloud Award, the Houston Methodist Clinical Scholar Award and a fund from MD Anderson Foundation. Funding Information: The authors appreciate the assistance of Jennifer M. Garrett, Rejani R. Nair, Jinghong Wang and Shixiang Wen of the Houston Methodist Neurological Institute and the Nantz National Alzheimer Center. We are grateful to the Nantz National Alzheimer Center patients and families for making this research possible. Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = nov,

day = "16",

doi = "10.1186/s40035-023-00387-5",

language = "English (US)",

volume = "12",

pages = "54",

journal = "Translational Neurodegeneration",

issn = "2047-9158",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease

AU - Faridar, Alireza

AU - Eid, Abdulmunaim M

AU - Thome, Aaron D

AU - Zhao, Weihua

AU - Beers, David R

AU - Pascual, Maria B

AU - Nakawah, Mohammad O

AU - Roman, Gustavo C

AU - Davis, Charles S

AU - Grundman, Michael

AU - Masdeu, Joseph C

AU - Appel, Stanley H

N1 - Funding Information: This research was supported by the Alzheimer’s Association Part-The-Cloud Award, the Houston Methodist Clinical Scholar Award and a fund from MD Anderson Foundation. Funding Information: The authors appreciate the assistance of Jennifer M. Garrett, Rejani R. Nair, Jinghong Wang and Shixiang Wen of the Houston Methodist Neurological Institute and the Nantz National Alzheimer Center. We are grateful to the Nantz National Alzheimer Center patients and families for making this research possible. Publisher Copyright: © 2023, The Author(s).

PY - 2023/11/16

Y1 - 2023/11/16

N2 - Trial registration : ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT05821153.

AB - Trial registration : ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT05821153.

KW - Humans

KW - Alzheimer Disease/drug therapy

KW - Pilot Projects

KW - Treatment Outcome

KW - Immunotherapy

UR - https://www.scopus.com/pages/publications/85176461023

UR - https://www.scopus.com/inward/citedby.url?scp=85176461023&partnerID=8YFLogxK

U2 - 10.1186/s40035-023-00387-5

DO - 10.1186/s40035-023-00387-5

M3 - Letter

C2 - 37968718

AN - SCOPUS:85176461023

SN - 2047-9158

VL - 12

SP - 54

JO - Translational Neurodegeneration

JF - Translational Neurodegeneration

IS - 1

M1 - 54

ER -

A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this